ERYTECH (ERYP) Reports TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

Go back to ERYTECH (ERYP) Reports TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis
(NASDAQ: ERYP) Delayed: 6.60 -0.27 (3.93%)
Previous Close $6.87    52 Week High
Open $6.50    52 Week Low
Day High $6.60    P/E N/A 
Day Low $6.50    EPS
Volume 4,957